During the past decade, St James' Institute of Oncology conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 5 clinical trials were completed, i.e. on average, 125% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "St James' Institute of Oncology" #1 sponsor was "Hoffmann-La Roche" with 2 trials, followed by "CCTU- Cancer Theme" with 1 trials sponsored, "Celgene" with 1 trials sponsored, "Heidelberg Pharma AG" with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "St James' Institute of Oncology" #1 collaborator was "Cancer Research UK" with 1 trials as a collaborator, "Celgene" with 1 trials as a collaborator and "NCRI Radiotherapy Trials QA (RTTQA) Group" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "St James' Institute of Oncology" are "Colorectal Cancer" (2 trials), "Advanced Breast Cancer" (1 trials), "Advanced Gastric Cancer" (1 trials), "Advanced Solid Tumours" (1 trials) and "Advanced/Metastatic Non-Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "St James' Institute of Oncology" in a lesser frequency.

Most popular intervention types in "St James' Institute of Oncology" are "Drug" (8 trials), "Biological" (2 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Gemcitabine" (2 trials), "Oxaliplatin" (2 trials), "5-Fluorouracil (5-FU)" (1 trials), "Abraxane (nab-paclitaxel)" (1 trials) and "Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody" (1 trials). Other intervention names were less common.

The vast majority of trials in "St James' Institute of Oncology" are 10 trials for "All" genders.

Currently, there are NaN active trials in "St James' Institute of Oncology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in St James' Institute of Oncology, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in St James' Institute of Oncology, 2 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".